

REUTERS

THOMSON REUTERS

LATEST NEWS [LATE U.S. TIPOFF HURTS U.N. SYRIA PROBE: ELBARADEI](#)**Top News**

Reuters top ten news stories delivered to your inbox each day.

[Subscribe](#)You are here: [Home](#) > [News](#) > [U.S.](#) > Article[HOME](#)[BUSINESS & FINANCE](#)[NEWS](#)[U.S.](#)[Politics](#)[International](#)[Technology](#)[Entertainment](#)[Sports](#)[Lifestyle](#)[Oddly Enough](#)[Environment](#)[Health](#)[Science](#)[Special Coverage](#)[Video](#)[Pictures](#)[You Witness](#)[Blogs](#)[Reader Feedback](#)**Do More With Reuters**[RSS](#) [Widgets](#)[Mobile](#)[Podcasts](#)[Newsletters](#)[You Witness News](#)**Partner Services**[CareerBuilder](#)[Affiliate Network](#)**Professional Products**[Support \(Customer Zone\)](#)

Do Enbrel, Humira, Or Remicade Cause Cancer In Children And Young Adults?

powered by BlogBurst

POSTED: Wednesday, June 04, 2008

FROM BLOG: [Drug Injury Watch](#) - Prescription Drug Side Effects News and Information from Attorney Tom Lamb

The following blog post is from an independent writer and is not connected with Reuters News. The opinions and views expressed herein are those of the author and are not endorsed by Reuters.com.

FDA Will Conduct A Safety Review Of These TNF Blockers To Investigate This Possible Link

(Posted by Tom Lamb at [DrugInjuryWatch.com](#))

On June 4, 2008 the FDA issued an "Early Communication About n Ongoing Safety Review of Tumor Necrosis Factor (TNF) Blockers" announcing that the agency has started an investigation into the potential link between certain TNF blockers used to treat Juvenile Idiopathic Arthritis (JIA), Crohn's disease, or other diseases and the development of lymphoma as well as other cancers in children and young adults.

According to this June 4 article, "[FDA Investigates Link Between TNF Blockers and Pediatric Cancer](#)", published online by *Medscape Medical News*:

Approximately 30 cases of cancer have been reported during a 10-year period extending through April 2008, occurring in pediatric patients receiving TNF blockers with other immunosuppressive therapies to treat juvenile idiopathic arthritis, Crohn's disease, or other conditions. About half of the cancers were Hodgkin's and non-Hodgkin's lymphomas; leukemia, melanoma, and solid organ malignancies were also reported, the agency said.

TNF blockers currently approved for pediatric use include etanercept (Enbrel, Immunex Corp, marketed by Amgen and Wyeth Pharmaceuticals), adalimumab (Humira, Abbott Laboratories), and infliximab (Remicade, Centocor, Inc). Makers of these products have been asked to supply the FDA with information regarding cancer cases in children receiving treatment....

As part of the 6-month review process, the agency has also contacted medical experts to assess the potential link between TNF blockers and cancer and also whether some children may be at particular risk for

[Reuters Media](#)[Financial Products](#)[Find a financial adviser](#)[About Thomson Reuters](#)

malignancy.

After this FDA safety review of Enbrel, Humira, and Remicade is complete, and the agency has reported its findings, we will let you know if there are any resulting recommendations to doctors and patients.

As with all serious side effects from prescription drugs, any adverse events related to the use of Enbrel (etanercept), Humira (adalimumab), or Remicade (infliximab) should be reported to the FDA's MedWatch reporting program by telephone at 1-800-FDA-1088, by fax at 1-800-FDA-0178, online at <http://www.fda.gov/medwatch>, or by mail to 5600 Fishers Lane, Rockville, MD 20852-9787.

[Read more from this blogger at Drug Injury Watch](#) | [Let us know what you think of this feature](#)

Reuters.com: [Help and Contact Us](#) | [Advertise With Us](#) | [Mobile](#) | [Newsletters](#) | [RSS](#)  | [Interactive TV](#) | [Labs](#) | [Reuters in S](#)

Thomson Reuters Corporate: [Copyright](#) | [Disclaimer](#) | [Privacy](#) | [Professional Products](#) | [Professional Products Support](#) | [About](#)

International Editions: [Africa](#) | [Arabic](#) | [Argentina](#) | [Brazil](#) | [Canada](#) | [China](#) | [France](#) | [Germany](#) | [India](#) | [Italy](#) | [Japan](#) | [Lat United States](#)

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please